No Data
Peering Into Humacyte's Recent Short Interest
Humacyte's (NYSE:HUMA) short percent of float has risen 17.24% since its last report. The company recently reported that it has 4.91 million shares sold short, which is 5.44% of all regular shares tha
Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP) Program
PDF Version – BioVascular Pancreas (BVP) product candidate is under development as a potential treatment for type 1 diabetes –– Humacyte's stem cell-derived islets observed to restore normal bloo
We're Not Very Worried About Humacyte's (NASDAQ:HUMA) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success wi
Express News | Humacyte Inc : TD Cowen Raises Target Price to $7.5 From $6
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $7.5
TD Cowen analyst Josh Jennings maintains $Humacyte(HUMA.US)$ with a buy rating, and adjusts the target price from $6 to $7.5.According to TipRanks data, the analyst has a success rate of 0.0% and a to
Humacyte Stock Slips 9%